Cell cycle checkpoints and their impact on anticancer therapeutic strategies
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Cells contain numerous pathways designed to protect them from the genomic instability or toxicity that can result when their DNA is damaged. The p53 tumor suppressor is particularly important for regulating passage through G 1 phase of the cell cycle, while other checkpoint regulators are important for arrest in S and G 2 phase. Tumor cells often exhibit defects in these checkpoint proteins, which can lead to hypersensitivity; proteins in this class include ataxia–telangiectasia mutatated (ATM), Meiotic recanbination 11 (Mre11), Nijmegen breakage syndrome 1 (Nbs 1), breast cancer susceptibility genes 1 and 2 (BRCA1), and (BRCA2). Consequently, tumors should be assessed for these specific defects, and specific therapy prescribed that has high probability of inducing response. Tumors defective in p53 are frequently considered resistant to apoptosis, yet this defect also provides an opportunity for targeted therapy. When their DNA is damaged, p53‐defective tumor cells preferentially arrest in S or G 2 phase where they are susceptible to checkpoint inhibitors such as caffeine and UCN‐01. These inhibitors preferentially abrogate cell cycle arrest in p53‐defective cells, driving them through a lethal mitosis. Wild type p53 can prevent abrogation of arrest by elevating levels of p21 waf1 and decreasing levels of cyclins A and B. During tumorigenesis, tumor cells frequently loose checkpoint controls and this facilitates the development of the tumor. However, these defects also represent an Achilles heel that can be targeted to improve current therapeutic strategies. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577 · cited 2×
“Ataxia telangiectasia is an autosomal recessive trait in which cells fail to arrest when damaged (mutated gene¼ATM) [Shiloh, 2003].”
BackgroundPeng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341 · cited 1×
“Phosphorylation of Cdc25C maintains it inactive in the cytosol complexed with 14-3-3 [Peng et al., 1997].”
BackgroundThe MRE11 complex: at the crossroads of DNA repair and checkpoint signalling
D'Amours, D., & Jackson, S. P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm805 · Cited by 874 · cited 1×
“These disorders include Nijmegen breakage syndrome (Nbs1) and ataxia telangiectasia-like disease (Mre11) [D’amours and Jackson, 2002].”
BackgroundThe Fanconi anaemia/BRCA pathway
D'Andrea, A. D., & Grompe, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc970 · Cited by 822 · cited 2×
“Additionally, inherited breast cancer susceptibility (BRCA1 and BRCA2) and Fanconi’s anemia also exhibit hypersensitivity to DNA damage; in the latter case, mutations affect eight different genes of which the FANCD1 gene is identical to BRCA2 [D’Andrea and Grompe, 2003].”
BackgroundRapid Destruction of Human Cdc25A in Response to DNA Damage
Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., & Lukas, J. (2000) · Science · doi:10.1126/science.288.5470.1425 · Cited by 787
Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance
Brown, E. J., & Baltimore, D. (2003) · Genes & Development · doi:10.1101/gad.1067403 · Cited by 511 · cited 1×
“It was shown that deletion of both ATM and ATR prevented arrest induced by g-irradiation, but cells incubated with aphidicolin still arrested [Brown and Baltimore, 2003].”
BackgroundUCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453 · cited 1×
“Similar results have been obtained with UCN-01 [Wang et al., 1996].”
ResultSelf-citationCaffeine inhibits the checkpoint kinase ATM
Blasina, A., Price, B. D., Turenne, G. A., & McGowan, C. H. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80486-2 · Cited by 295
Akinaga, S., Nomura, K., Gomi, K., & Okabe, M. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685833 · Cited by 118
Cited by
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
“and significantly affect the efficacy of anticancer treatmen”
BackgroundDeath by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, C. X., Janetka, J. W., & Piwnica-Worms, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.009 · Cited by 271
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 266
Origanti, S., Cai, S.-R., Munir, A. Z., White, L. S., & Piwnica-Worms, H. (2013) · Oncogene · doi:10.1038/onc.2012.84 · Cited by 74
Metadata
- Authors
- Eastman, A.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2003-11-04
- Volume
- 91
- Issue
- 2
- Pages
- 223-231
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2107440467
- Cited by
- 159
- References
- 9
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.